Let’s face it, 2020 was a big year in the world of diagnostics. Spurred on by the need to have adequate testing of COVID-19, in vitro diagnostics took center stage.
One of the key factors that played a role in diagnostics’ prominence was FDA’s plan for emergency use authorizations of potential tests. The market was flooded with EUA’s for COVID-19-related tests.
EUA’s dominated MD+DI’s coverage for the better part of the year.
And for even more proof that diagnostics played a big in healthcare this year, one has to look no further than Cue Health’s massive $100 million Series C financing round. The San Diego, CA-based company garnered a great deal of interest from investors because of its rapid COVID-19 test.